Green Days Pollutec 2025

7–10 Oct 2025 | Eurexpo Lyon, France

Bassam Damaj

President & CEO

Veos Pharmaceuticals, SL

Madrid, Madrid, Spain

1 profile visitCompany

We develop OliQuell™-coated filters that cut CO₂, VOCs, and odors in sealed recirculating systems for mobility, HVAC, industry, and oil & gas

My organisation

Veos Pharmaceuticals is a circular biotech company developing nature-based solutions for air purification, emissions reduction, sustainable water and soil regeneration, and aging. Our flagship platform, OliQuell™, is a patented, biodegradable powder derived from olive-waste and functional bioactives. It passively reduces CO₂, H₂S, VOCs, and odors in closed systems such as HVAC filters, EV cabins, biogas digesters, and irrigation water—without the need for active energy input or infrastructure changes. OliQuell™ is validated in automotive, agriculture, and wastewater treatment settings, including a recent Volvo trial showing up to 45% CO₂ inhibition under sealed recirculation. It is fully compatible with circular and CCUS strategies. Veos is GMP-compliant, IP-protected, and actively operating in the EU, North America, and now expanding into Japan and Korea through pilot partnerships and OEM integrations in energy, smart mobility, and water reuse.
Read more

About me

Dr. Bassam Damaj is a biotech entrepreneur and pharmaceutical innovator with over 25 years of experience building science-based ventures.
He has founded 7 companies, led 3 IPOs, and raised over $500M across the U.S., EU, and MENA.

As CEO of Veos Pharmaceuticals, he leads the development of ThymoTropin™, the first natural and clinically validated myostatin regulator, designed to combat sarcopenia by preserving muscle growth, strength, and endurance in aging populations.

His expertise spans biotechnology, functional ingredients, clinical development, and global strategic partnerships — with a focus on healthy aging and longevity.

Social media

Marketplace (3)